Medical gear maker Getinge misses core profit estimates in fourth quarter (updated)

Getinge publ AB

27/01/2026 07:08

Adds share reaction in paragraph 2, CEO comments on costs, prices and US government shudown in paragraphs 3, 5 and 6, context in paragraph 7

Getinge shares fall 6% after it misses Q4 profit expectations

Tariffs, FX effects impacted annual results by 1 billion Swedish crowns

Getinge plans further price hikes to offset tariff costs in 2026

US government shutdown delayed some projects in Q4, CEO Perjos says

By Marta Frackowiak

Jan 27 (Reuters) - Medical equipment maker Getinge GETIb.ST missed market expectations for fourth-quarter earnings on Tuesday, after U.S. tariffs and the weak dollar left a dent of around 1 billion Swedish crowns ($112 million) in its annual results.

Shares of the Swedish company, which makes more than a third of its sales in the United States, fell 6% and were at the bottom of Europe's benchmark STOXX 600 index .STOXX as of 1000 GMT.

Tariffs cost the company around 370 million crowns in 2025, while currency exchange, mostly from converting U.S. dollars into crowns, had an impact of just over 600 million crowns, CEO Mattias Perjos said in an interview with Reuters.

Getinge's adjusted earnings before interest, taxes and amortisation fell 16% to 1.81 billion crowns in the fourth quarter, below analysts' forecast of 1.87 billion crowns in a company-provided poll.

The company, which makes products for surgery, intensive care and sterilisation, aims to hike prices by around 2% in 2026 to combat tariff costs, after raising them by more than 2% last year, Perjos said during a call with analysts.

The U.S. government shutdown in the fourth quarter, which temporarily halted funding from the National Institutes of Health, also led to delays in larger projects in Getinge's life sciences business, though none were cancelled, he told Reuters.

The government might be headed for a partial shutdown again after the fatal shooting of a second U.S. citizen by federal immigration officers in Minnesota spawned a partisan fight over funding for the Department of Homeland Security.

Getinge's quarterly orders rose 2.3% organically, marking an eighth straight quarter of growth, albeit at a slower pace than a year earlier. That was driven by demand for consumables used in extracorporeal life support therapies and strong sales of transplant care products and ventilators, it said.

Getinge, whose customers include hospitals and life science institutions, forecast organic sales growth of 3% to 5% for 2026, compared with 4.9% last year, and proposed an annual dividend of 4.75 crowns per share.

($1 = 8.9152 Swedish crowns)

(Reporting by Marta Frackowiak in Gdansk; Editing by Milla Nissi-Prussak)

((marta.frackowiak@thomsonreuters.com))